Cleared Traditional

K230594 - Tigereye ST CTO-Crossing Catheter (FDA 510(k) Clearance)

Apr 2023
Decision
53d
Days
Class 2
Risk

K230594 is an FDA 510(k) clearance for the Tigereye ST CTO-Crossing Catheter. This device is classified as a Catheter For Crossing Total Occlusions (Class II - Special Controls, product code PDU).

Submitted by Avinger, Inc. (Redwood City, US). The FDA issued a Cleared decision on April 25, 2023, 53 days after receiving the submission on March 3, 2023.

This device falls under the Cardiovascular FDA review panel. Regulated under 21 CFR 870.1250. To Facilitate The Intraluminal Placement Of Conventional Guidewires Beyond Stenotic Lesions (including Subchronic And Chronic Total Occlusions) In The Peripheral Vasculature Prior To Further Percutaneous Intervention, Such As Angioplasty, Atherectomy Or Stent Placement..

Submission Details

510(k) Number K230594 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 03, 2023
Decision Date April 25, 2023
Days to Decision 53 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF

Device Classification

Product Code PDU — Catheter For Crossing Total Occlusions
Device Class Class II - Special Controls
CFR Regulation 21 CFR 870.1250
Definition To Facilitate The Intraluminal Placement Of Conventional Guidewires Beyond Stenotic Lesions (including Subchronic And Chronic Total Occlusions) In The Peripheral Vasculature Prior To Further Percutaneous Intervention, Such As Angioplasty, Atherectomy Or Stent Placement.